Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1...

Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase...

Prof Jorge Cortes - Augusta University, Augusta, USA

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory...

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

$AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )$

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

$CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )$

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Patient reported outcomes for the CANDOR trial for multiple myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

Patient reported outcomes for the CANDOR trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CTC count as a prognostic marker for androgen deprivation plus orteronel or...

Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation...

Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

More from ecancer